65,437 trials
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From…
Hypophosphatasia (HPP)
Primary: Change in Rickets Severity on Skeletal Radiographs From Baseline to Week 24 as Measured by the Radiographic Global Impression of Change (RGI-C) Scale — 0; 2.00 units on…
Menorrhagia
Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants
Non-Hodgkin's Lymphoma
Primary: Progression Free Survival — 389; 334 days — p=0.039
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI — 1.2; 0.9; 1.1; 0.9 Units on a scale
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Asthma · Acute Asthma · Reactive Airway Exacerbation
Primary: Median Change in Asthma Score 2 Hours After Intervention — -3; -3 Units on a scale — p=0.44
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
Diabetes · Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) at Month 12 — 8.45; 8.55; 8.63; 7.64 percentage (%) of total haemoglobin
Fatigue
Primary: Participants Considered "Responders" (Scored 1 or 2) on Clinical Global Impressions Scale — 19; 1 participants considered "responders"
Wounds
Primary: Time to Complete Wound Closure (Epithelialization) — 15; 15 days
Rheumatoid Arthritis
Primary: Estimation of the Direct and Indirect Cost Incurred by Adalimumab Treatment — 272.99; 1162.62; 2662.73; 659.13 Euros
Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment — 60.5; 52.9; 100.0…
Acne Vulgaris
Primary: Local Tolerability - Skin Dryness — 28; 26; 2; 4 participants